In the last trading session, 1.62 million Viridian Therapeutics Inc (NASDAQ:VRDN) shares changed hands as the company’s beta touched 1.36. With the company’s per share price at $16.86 changed hands at -$0.91 or -5.12% during last session, the market valuation stood at $1.34B. VRDN’s last price was a discount, traded about -61.33% off its 52-week high of $27.20. The share price had its 52-week low at $11.40, which suggests the last value was 32.38% up since then. When we look at Viridian Therapeutics Inc’s average trading volume, we note the 10-day average is 1.46 million shares, with the 3-month average coming to 1.33 million.
Analysts gave the Viridian Therapeutics Inc (VRDN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.24. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended VRDN as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Viridian Therapeutics Inc’s EPS for the current quarter is expected to be -1.0.
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Instantly VRDN was in red as seen at the end of in last trading. With action -15.99%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -12.05%, with the 5-day performance at -15.99% in the red. However, in the 30-day time frame, Viridian Therapeutics Inc (NASDAQ:VRDN) is -11.15% down. Looking at the short shares, we see there were 12.05 million shares sold at short interest cover period of 7.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 23.36% from its current market value. According to analyst projections, VRDN’s forecast low is 19 with 28 as the target high. To hit the forecast high, the stock’s price needs a -66.07% plunge from its current level, while the stock would need to soar -12.69% for it to hit the projected low.
Viridian Therapeutics Inc (VRDN) estimates and forecasts
Data shows that the Viridian Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 14.77% over the past 6 months, a 24.11% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 0.18% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 48.77k. 7 analysts are of the opinion that Viridian Therapeutics Inc’s revenue for the current quarter will be 42.86k. The company’s revenue for the corresponding quarters a year ago was 72k and 72k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -32.26%. The estimates for the next quarter sales put growth at -40.47%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.35%. The 2025 estimates are for Viridian Therapeutics Inc earnings to increase by 24.07%.
VRDN Dividends
Viridian Therapeutics Inc is expected to release its next quarterly earnings report in February.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.01% of Viridian Therapeutics Inc shares while 112.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.97%. There are 112.96% institutions holding the Viridian Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.6686% of the shares, roughly 9.57 million VRDN shares worth $124.55 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8129% or 4.77 million shares worth $62.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Health Care . With 2.24 shares estimated at $37.82 million under it, the former controlled 2.83% of total outstanding shares. On the other hand, Fidelity Select Portfolios – Health Care held about 2.52% of the shares, roughly 2.0 shares worth around $33.72 million.
